PRIMARY STUDY
Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder
Key Findings: This secondary analysis from a study on the efficacy of using cannabinoid medications, namely nabiximols, to treat cannabis use disorder (CUD) found that counseling plus pharmacotherapy had the best improvement in treatment outcomes. Other findings were that younger, males, and those with sleep concerns benefitted more from additional treatment services.
Type of Study: Double Blind Clinical Trial
Study Sample Size: 128
Study Result: Positive
Research Location(s): Australia
Year of Pub: 2022
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Pharma THC:CBD
Phytocannabinoid Source: Not Applicable
Chemotype: Chemotype II
Sub-Ratio: 2.7 mg THC : 2.5 mg CBD
Dosage: Up to 32 oromucosal sprays daily, each spray containing 2.7 mg THC and 2.5 mg CBD
Route of Administration: Sublingual/Oromucosal
Citation: Mills L, et al. Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder. Subst Abuse Treat Prev Policy. 2022; 17:67. doi: 10.1186/s13011-022-00493-z
Authors: Mills L, Dunlop A, Montebello M, Copeland J, Bruno R, Jefferies M, Mcgregor I, Lintzeris N
